Logo image of PMVP

PMV PHARMACEUTICALS INC (PMVP) Stock Fundamental Analysis

NASDAQ:PMVP - Nasdaq - US69353Y1038 - Common Stock - Currency: USD

1.13  +0.06 (+5.61%)

Fundamental Rating

3

PMVP gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 558 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PMVP as it has an excellent financial health rating, but there are worries on the profitability. PMVP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PMVP had negative earnings in the past year.
In the past year PMVP has reported a negative cash flow from operations.
In the past 5 years PMVP always reported negative net income.
PMVP had a negative operating cash flow in each of the past 5 years.
PMVP Yearly Net Income VS EBIT VS OCF VS FCFPMVP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of PMVP (-35.68%) is better than 60.75% of its industry peers.
Looking at the Return On Equity, with a value of -38.02%, PMVP is in the better half of the industry, outperforming 72.04% of the companies in the same industry.
Industry RankSector Rank
ROA -35.68%
ROE -38.02%
ROIC N/A
ROA(3y)-28.39%
ROA(5y)-22.41%
ROE(3y)-31.23%
ROE(5y)-24.41%
ROIC(3y)N/A
ROIC(5y)N/A
PMVP Yearly ROA, ROE, ROICPMVP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30

1.3 Margins

PMVP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PMVP Yearly Profit, Operating, Gross MarginsPMVP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, PMVP has more shares outstanding
The number of shares outstanding for PMVP has been increased compared to 5 years ago.
There is no outstanding debt for PMVP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PMVP Yearly Shares OutstandingPMVP Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PMVP Yearly Total Debt VS Total AssetsPMVP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -0.63, we must say that PMVP is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PMVP (-0.63) is better than 60.39% of its industry peers.
There is no outstanding debt for PMVP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.63
ROIC/WACCN/A
WACCN/A
PMVP Yearly LT Debt VS Equity VS FCFPMVP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 16.75 indicates that PMVP has no problem at all paying its short term obligations.
PMVP's Current ratio of 16.75 is amongst the best of the industry. PMVP outperforms 89.61% of its industry peers.
PMVP has a Quick Ratio of 16.75. This indicates that PMVP is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 16.75, PMVP belongs to the top of the industry, outperforming 89.61% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.75
Quick Ratio 16.75
PMVP Yearly Current Assets VS Current LiabilitesPMVP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.28% over the past year.
EPS 1Y (TTM)11.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PMVP will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.82% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-38.09%
EPS Next 2Y-25.49%
EPS Next 3Y-11.88%
EPS Next 5Y9.82%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PMVP Yearly Revenue VS EstimatesPMVP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2027 2028 2029 2030 2031 2032 100M 200M 300M
PMVP Yearly EPS VS EstimatesPMVP Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PMVP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PMVP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PMVP Price Earnings VS Forward Price EarningsPMVP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PMVP Per share dataPMVP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PMVP's earnings are expected to decrease with -11.88% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-25.49%
EPS Next 3Y-11.88%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PMVP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PMV PHARMACEUTICALS INC

NASDAQ:PMVP (6/24/2025, 1:39:06 PM)

1.13

+0.06 (+5.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)08-06 2025-08-06/bmo
Inst Owners65.76%
Inst Owner Change-4.21%
Ins Owners3.23%
Ins Owner Change0%
Market Cap58.70M
Analysts85.45
Price Target5.61 (396.46%)
Short Float %1.95%
Short Ratio3.34
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.47%
Min EPS beat(2)-15.92%
Max EPS beat(2)10.97%
EPS beat(4)2
Avg EPS beat(4)21.53%
Min EPS beat(4)-15.92%
Max EPS beat(4)94.4%
EPS beat(8)6
Avg EPS beat(8)21.58%
EPS beat(12)10
Avg EPS beat(12)16.89%
EPS beat(16)11
Avg EPS beat(16)11.37%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.94%
PT rev (3m)-31.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.58%
EPS NY rev (1m)-3.78%
EPS NY rev (3m)1.49%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.37
P/tB 0.37
EV/EBITDA N/A
EPS(TTM)-1.18
EYN/A
EPS(NY)-1.8
Fwd EYN/A
FCF(TTM)-1.03
FCFYN/A
OCF(TTM)-1.03
OCFYN/A
SpS0
BVpS3.08
TBVpS3.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.68%
ROE -38.02%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.39%
ROA(5y)-22.41%
ROE(3y)-31.23%
ROE(5y)-24.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.75
Quick Ratio 16.75
Altman-Z -0.63
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)875.85%
Cap/Depr(5y)621.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.33%
EPS Next Y-38.09%
EPS Next 2Y-25.49%
EPS Next 3Y-11.88%
EPS Next 5Y9.82%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-18.34%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y21.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y12.19%
OCF growth 3YN/A
OCF growth 5YN/A